Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 245

1.

Nitrite potently inhibits hypoxic and inflammatory pulmonary arterial hypertension and smooth muscle proliferation via xanthine oxidoreductase-dependent nitric oxide generation.

Zuckerbraun BS, Shiva S, Ifedigbo E, Mathier MA, Mollen KP, Rao J, Bauer PM, Choi JJ, Curtis E, Choi AM, Gladwin MT.

Circulation. 2010 Jan 5;121(1):98-109. doi: 10.1161/CIRCULATIONAHA.109.891077. Epub 2009 Dec 21.

2.

P21-dependent protective effects of a carbon monoxide-releasing molecule-3 in pulmonary hypertension.

Abid S, Houssaïni A, Mouraret N, Marcos E, Amsellem V, Wan F, Dubois-Randé JL, Derumeaux G, Boczkowski J, Motterlini R, Adnot S.

Arterioscler Thromb Vasc Biol. 2014 Feb;34(2):304-12. doi: 10.1161/ATVBAHA.113.302302. Epub 2013 Dec 12.

3.

Dietary nitrate ameliorates pulmonary hypertension: cytoprotective role for endothelial nitric oxide synthase and xanthine oxidoreductase.

Baliga RS, Milsom AB, Ghosh SM, Trinder SL, Macallister RJ, Ahluwalia A, Hobbs AJ.

Circulation. 2012 Jun 12;125(23):2922-32. doi: 10.1161/CIRCULATIONAHA.112.100586. Epub 2012 May 9.

5.
6.

YC-1 attenuates hypoxia-induced pulmonary arterial hypertension in mice.

Huh JW, Kim SY, Lee JH, Lee YS.

Pulm Pharmacol Ther. 2011 Dec;24(6):638-46. doi: 10.1016/j.pupt.2011.09.003. Epub 2011 Sep 24.

PMID:
21963997
7.

Sustained therapeutic hypercapnia attenuates pulmonary arterial Rho-kinase activity and ameliorates chronic hypoxic pulmonary hypertension in juvenile rats.

Peng G, Ivanovska J, Kantores C, Van Vliet T, Engelberts D, Kavanagh BP, Enomoto M, Belik J, Jain A, McNamara PJ, Jankov RP.

Am J Physiol Heart Circ Physiol. 2012 Jun 15;302(12):H2599-611. doi: 10.1152/ajpheart.01180.2011. Epub 2012 Apr 13.

8.

Effect of chronic sodium nitrite therapy on monocrotaline-induced pulmonary hypertension.

Pankey EA, Badejo AM, Casey DB, Lasker GF, Riehl RA, Murthy SN, Nossaman BD, Kadowitz PJ.

Nitric Oxide. 2012 Jun 30;27(1):1-8. doi: 10.1016/j.niox.2012.02.004. Epub 2012 Mar 14.

9.

Pulmonary vasodilator responses to sodium nitrite are mediated by an allopurinol-sensitive mechanism in the rat.

Casey DB, Badejo AM Jr, Dhaliwal JS, Murthy SN, Hyman AL, Nossaman BD, Kadowitz PJ.

Am J Physiol Heart Circ Physiol. 2009 Feb;296(2):H524-33. doi: 10.1152/ajpheart.00543.2008. Epub 2008 Dec 12.

10.

Nitrite-generated NO circumvents dysregulated arginine/NOS signaling to protect against intimal hyperplasia in Sprague-Dawley rats.

Alef MJ, Vallabhaneni R, Carchman E, Morris SM Jr, Shiva S, Wang Y, Kelley EE, Tarpey MM, Gladwin MT, Tzeng E, Zuckerbraun BS.

J Clin Invest. 2011 Apr;121(4):1646-56. doi: 10.1172/JCI44079. Epub 2011 Mar 23.

11.

Intermedin modulates hypoxic pulmonary vascular remodeling by inhibiting pulmonary artery smooth muscle cell proliferation.

Mao SZ, Fan XF, Xue F, Chen R, Chen XY, Yuan GS, Hu LG, Liu SF, Gong YS.

Pulm Pharmacol Ther. 2014 Feb;27(1):1-9. doi: 10.1016/j.pupt.2013.06.004. Epub 2013 Jun 22.

PMID:
23796770
12.

Analysis of responses to the Rho-kinase inhibitor Y-27632 in the pulmonary and systemic vascular bed of the rat.

Casey DB, Badejo AM, Dhaliwal JS, Sikora JL, Fokin A, Golwala NH, Greco AJ, Murthy SN, Nossaman BD, Hyman AL, Kadowitz PJ.

Am J Physiol Heart Circ Physiol. 2010 Jul;299(1):H184-92. doi: 10.1152/ajpheart.00181.2009. Epub 2010 Apr 30.

13.

Lysyl oxidases play a causal role in vascular remodeling in clinical and experimental pulmonary arterial hypertension.

Nave AH, Mižíková I, Niess G, Steenbock H, Reichenberger F, Talavera ML, Veit F, Herold S, Mayer K, Vadász I, Weissmann N, Seeger W, Brinckmann J, Morty RE.

Arterioscler Thromb Vasc Biol. 2014 Jul;34(7):1446-58. doi: 10.1161/ATVBAHA.114.303534. Epub 2014 May 15.

14.

Effects of U50,488H on hypoxia pulmonary hypertension and its underlying mechanism.

Li J, Zhang P, Zhang QY, Zhang SM, Guo HT, Bi H, Wang YM, Sun X, Liu JC, Cheng L, Cui Q, Yu SQ, Kaye AD, Yi DH, Pei JM.

Vascul Pharmacol. 2009 Aug-Sep;51(2-3):72-7. doi: 10.1016/j.vph.2009.03.003. Epub 2009 Apr 5.

PMID:
19351568
15.

Oxymatrine prevents hypoxia- and monocrotaline-induced pulmonary hypertension in rats.

Zhang B, Niu W, Xu D, Li Y, Liu M, Wang Y, Luo Y, Zhao P, Liu Y, Dong M, Sun R, Dong H, Li Z.

Free Radic Biol Med. 2014 Apr;69:198-207. doi: 10.1016/j.freeradbiomed.2014.01.013. Epub 2014 Jan 15.

PMID:
24440469
16.

Nitrite in pulmonary arterial hypertension: therapeutic avenues in the setting of dysregulated arginine/nitric oxide synthase signalling.

Zuckerbraun BS, George P, Gladwin MT.

Cardiovasc Res. 2011 Feb 15;89(3):542-52. doi: 10.1093/cvr/cvq370. Epub 2010 Dec 22. Review.

17.

Therapeutic efficacy of AAV1.SERCA2a in monocrotaline-induced pulmonary arterial hypertension.

Hadri L, Kratlian RG, Benard L, Maron BA, Dorfmüller P, Ladage D, Guignabert C, Ishikawa K, Aguero J, Ibanez B, Turnbull IC, Kohlbrenner E, Liang L, Zsebo K, Humbert M, Hulot JS, Kawase Y, Hajjar RJ, Leopold JA.

Circulation. 2013 Jul 30;128(5):512-23. doi: 10.1161/CIRCULATIONAHA.113.001585. Epub 2013 Jun 26.

19.

Exogenous nitric oxide upregulates p21(waf1/cip1) in pulmonary microvascular smooth muscle cells.

Stotz WH, Li D, Johns RA.

J Vasc Res. 2004 May-Jun;41(3):211-9. Epub 2004 Mar 26.

PMID:
15051933
20.

Impaired vasoconstriction and nitric oxide-mediated relaxation in pulmonary arteries of hypoxia- and monocrotaline-induced pulmonary hypertensive rats.

Mam V, Tanbe AF, Vitali SH, Arons E, Christou HA, Khalil RA.

J Pharmacol Exp Ther. 2010 Feb;332(2):455-62. doi: 10.1124/jpet.109.160119. Epub 2009 Nov 13.

Supplemental Content

Support Center